The article discusses the role of the mechanistic target of rapamycin (mTOR) pathway in aging and age-related diseases. mTOR is a nutrient response pathway that regulates cellular growth and metabolism. Inhibition of mTOR has been shown to extend lifespan in model organisms and protect against age-related pathologies. The mTOR pathway consists of two complexes, mTORC1 and mTORC2, which have distinct functions and regulators. mTORC1 is activated by insulin and growth factors and is involved in mRNA translation, protein synthesis, lipid biosynthesis, and glucose metabolism. mTORC2 is less well understood but is thought to be involved in metabolic regulation. mTORC1 inhibition has been linked to longevity and healthspan, and it may slow aging by reducing mRNA translation, promoting autophagy, enhancing stress resistance, regulating mitochondrial function, and modulating inflammation. mTORC1 inhibition has also shown positive effects on age-related diseases such as neurodegenerative disorders, cancer, and cardiovascular disease. However, side effects of mTOR inhibitors, such as hyperlipidaemia and hyperglycaemia, must be considered before their use in healthy individuals. The article highlights the potential of mTOR inhibitors as therapeutic agents for aging and age-related diseases, but emphasizes the need for further research to optimize dosage and duration of treatment.The article discusses the role of the mechanistic target of rapamycin (mTOR) pathway in aging and age-related diseases. mTOR is a nutrient response pathway that regulates cellular growth and metabolism. Inhibition of mTOR has been shown to extend lifespan in model organisms and protect against age-related pathologies. The mTOR pathway consists of two complexes, mTORC1 and mTORC2, which have distinct functions and regulators. mTORC1 is activated by insulin and growth factors and is involved in mRNA translation, protein synthesis, lipid biosynthesis, and glucose metabolism. mTORC2 is less well understood but is thought to be involved in metabolic regulation. mTORC1 inhibition has been linked to longevity and healthspan, and it may slow aging by reducing mRNA translation, promoting autophagy, enhancing stress resistance, regulating mitochondrial function, and modulating inflammation. mTORC1 inhibition has also shown positive effects on age-related diseases such as neurodegenerative disorders, cancer, and cardiovascular disease. However, side effects of mTOR inhibitors, such as hyperlipidaemia and hyperglycaemia, must be considered before their use in healthy individuals. The article highlights the potential of mTOR inhibitors as therapeutic agents for aging and age-related diseases, but emphasizes the need for further research to optimize dosage and duration of treatment.